Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): Possible role in hypersensitivity reactions

Annals of Oncology

Volumn 14, Issue 9, 2003, Pages 1430-1437

  Chanan Khan, Asher ^a,c   Szebeni, J ^b   Savay, S ^b   Liebes, L ^a   Rafique, N M ^a   Alving, C R ^b   Muggia, F M ^a  

^a NEW YORK UNIVERSITY   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Allergy; Anaphylatoxins; Cancer chemotherapy; Doxorubicin; Hypersensitivity reactions; Liposomes

Indexed keywords

ANTIHISTAMINIC AGENT; CIMETIDINE; COMPLEMENT MEMBRANE ATTACK COMPLEX; DIPHENHYDRAMINE; DOXORUBICIN; HYDROCORTISONE; LIPOSOME; ONDANSETRON; PROTEIN S; STEROID; TROPISETRON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG FORMULATION; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; SOLID TUMOR; SYMPTOMATOLOGY;

EID: 0141725521     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg374     Document Type: Article

References (30)

1. Dezube BJ. Safety assessment: Doxil® (doxorubicin HC1 liposome injection) in refractory AIDS-related Kaposi's sarcoma. In Doxil Clinical Series, Vol. 1. Califon, NJ: Gardiner-Caldwell SynerMed 1996; 1-8.
2. Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 2001; 3: 156-162.
3. Lyass O, Uziely B, Ben-Yosef R et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037-1047.
4. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19: 424-436.
5. Lyass O, Hubert A, Gabizon AA. Phase I study of Doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res 2001; 7: 3040-3046.
6. Muggia FM, Blessing JA, Sorosky et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002; 20: 2360-2364.
7. Gabizon A, Catane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-992.
8. Gabizon A, Isacson R, Libson E et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 1994; 33: 779-786.
9. Uziely B, Jeffers S, Isacson R et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777-1785.
10. Gabizon AA, Muggia FM. Initial clinical evaluation of pegylated-liposomal doxorubicin in solid tumors. In Woodle MC, Storm G (eds): Long Circulating Liposomes: Old Drugs, New Therapeutics. Austin, TX: Springer-Verlag and Landes Bioscience 1998; 165-174.
11. Northfelt DW, Dezube BJ, Thommes JA et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15: 653-659.
12. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-993.
13. Koukouraski MI, Kourkouraki S, Giatromanolaki A et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 1999; 17: 3512-3521.
14. Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-3100.
15. Hubert A, Lyass O, Pode D et al. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 2000; 11: 123-127.
16. Lyass O, Uziely B, Ben-Yosef R et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037-1047.
17. de Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996; 10 (Suppl 2): S93-S96.
18. Skubitz KM, Skubitz AP. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998; 9: 45-50.
19. ALZA Pharmaceuticals, I. Doxil Package Insert. Mountain View, CA, USA 2000.
20. Szebeni J, Baranyi B, Savay S et al. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®). J Liposome Res 2000; 10: 347-361.
21. Szebeni J, Fontana JL, Wassef NM et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999; 99: 2302-2309.
22. Szebeni J, Baranyi B, Savay S et al. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol 2000; 279: H1319-H1328.
23. Muller-Eberhard HJ. The membrane attack complex. Springer Semin Immunopathol 1984; 7: 93-141.
24. Buyon JP, Tamerius J, Belmont HM et al. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992; 35: 1028-1037.
25. Rosner B. Fundamentals of Biostatistics, 2nd edition. Boston, MA: Duxbury Press 1986; 424-428.
26. Szebeni J. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 1998; 15: 57-88.
27. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998; 90: 300-306.
28. Szebeni J, Alving CR, Savay S et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001; 1: 721-735.
29. Sculier JP, Coune A, Brassinne C et al. Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data. J Clin Oncol 1986; 4: 789-797.
30. Brouwers AH, DeJong DJ, Dams ET et al. Tc-99m-PEG-liposomes for the evaluation of colitis in Crohn's disease. J Drug Target 2000; 8: 225-233.